

THE ELDER CARE MARKET: PRODUCTS AND SERVICES



HLC062C
February 2016

Peggy Lehr
Project Analyst

ISBN: 1-62296-231-1



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
EMPHASIS OF THE REPORT	6
HEALTHCARE	6
HOUSING	6
ASSISTIVE TECHNOLOGY	7
<i>SUMMARY TABLE U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, 2015 AND 2020 (%)</i>	9
CHAPTER 3 OVERVIEW OF GLOBAL ELDERLY POPULATION	11
DEFINITIONS	11
TRENDS IN GLOBAL AGING	11
HEALTHCARE AND AGING	12
Volunteer Care	12
In-home Care	12
Hospice Care	13
THE GLOBAL ENVIRONMENT FOR THE ELDERLY	13
GLOBAL SOCIAL ENVIRONMENT	13
Intergenerational Living Issues in Developing Countries	13
Intergenerational Living Issues in Developed Countries	13
GLOBAL HOUSING REALITY FOR THE ELDERLY	14
Europe	14
China	14
GLOBAL ECONOMIC REALITY FOR THE ELDERLY	14
Economic Trends for Elderly Outside the U.S.	14
Europe	14
India	15
Japan	15
Economic Trends for U.S. Elderly	15
GLOBAL DEMOGRAPHIC TRENDS, BY COUNTRY	16
<i>TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES, 2014 (MILLIONS/%)</i>	16
THE ELDERLY IN THE U.S.	16
DEMOGRAPHICS IN THE U.S.	16

TOPIC	PAGE NO.
<i>TABLE 2 ESTIMATED ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS, WITH PERCENT OF POPULATION BY U.S. STATE, 2014 (POPULATION/%)</i>	17
HEALTH OF THE U.S. ELDERLY	18
U.S. Health Trends	18
Discrepancies in Minority Health Status	18
Elderly Living with Chronic Health Conditions	19
SHIFTING DEMOGRAPHICS IN THE U.S.	19
Racial and Ethnic Changes	19
GOVERNMENT LEGISLATION AND PROGRAMS AIMED AT THE ELDERLY	20
AMERICANS WITH DISABILITIES ACT	20
ADA and Employee Rights	20
TELECOMMUNICATIONS ACT OF 1934	21
FAIR HOUSING ACT	21
AIR CARRIER ACCESS ACT	21
VOTING ACCESSIBILITY FOR THE ELDERLY AND HANDICAPPED ACT OF 1984	21
ARCHITECTURAL BARRIERS ACT OF 1968	21
MEDICAL DEVICE LEGISLATION	21
AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009	22
AFFORDABLE CARE ACT	22
U.S. GOVERNMENT-SPONSORED AND PRIVATELY SPONSORED NUTRITION PROGRAMS	22
END-OF-LIFE CONSIDERATIONS	23
LEGAL MATTERS	23
HOSPICE CARE	23
INTERMENT ISSUES	24
CHAPTER 4 INDUSTRY TRENDS BY SECTOR - HEALTHCARE	26
U.S. HEALTHCARE FOR INDIVIDUALS OVER 65	26
<i>TABLE 3 U.S. MARKET FOR HEALTHCARE MEDICATIONS, PRODUCTS AND SURGICAL PROCEDURES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 (\$ MILLIONS/%)</i>	27
ARTHRITIS	27
CURRENT TREATMENTS	27
Medications	28
Rheumatoid Arthritis	28
COX2 Inhibitors	28
Disease-modifying Antirheumatic Drugs	28
Biologics	29
Corticosteroids	29
NSAIDs	29
Osteoarthritis	29
THE FUTURE BURDEN OF ARTHRITIS IN THE U.S.	30
<i>FIGURE 1 FUTURE BURDEN OF ARTHRITIS FOR INDIVIDUALS OVER 65 IN THE U.S. BY GENDER, 2010-2030 (\$ MILLIONS)</i>	30
ARTHRITIS TREATMENT MARKET PROJECTIONS	30
<i>TABLE 4 U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	31

TOPIC	PAGE NO.
CARDIOVASCULAR DISEASES	31
CARDIOVASCULAR DISEASE IN THE U.S.	31
Risk Factors	32
Current Treatments for Heart Disease	32
Surgical Options	32
Heart Disease Medications	33
<i>TABLE 5 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND MANUFACTURER</i>	33
CARDIOVASCULAR TREATMENT MARKET ANALYSIS	35
<i>TABLE 6 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS, THROUGH 2020 (\$ MILLIONS)</i>	36
<i>TABLE 7 U.S. MARKET FOR CARDIOVASCULAR MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	36
CANCER	36
TYPES OF CANCERS	37
GLOBAL RISK FACTORS	37
CANCER TREATMENT MARKET ANALYSIS	37
<i>TABLE 8 LEADING CANCER DRUG PRODUCTS, BY MANUFACTURER AND INDICATION, 2015</i>	38
MARKET ANALYSIS FOR U.S. CANCER DRUGS	40
<i>TABLE 9 U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH 2020 (\$ MILLIONS)</i>	40
<i>TABLE 10 U.S. MARKET FOR CANCER DRUGS FOR INDIVIDUALS OVER AGE 65, THROUGH 2020 (\$ MILLIONS)</i>	41
DIABETES	41
TYPE 2 DIABETES INTERNATIONALLY	41
Type 2 Diabetes in Asia	42
PREVALENCE OF TYPE 2 DIABETES IN THE U.S.	42
CURRENT TREATMENT OF DIABETES	42
Type 1 Diabetes	42
Insulin	42
Insulin Administration Devices	43
Type 2 Diabetes	43
Sulfonylureas	43
<i>TABLE 11 SULFONYLUREAS</i>	44
Biguanides	44
<i>TABLE 12 BIGUANIDES</i>	44
Alpha-Glucosidase Inhibitor	45
Glitazones	45
Prandial Glucose Regulators	45
GLP-1 Analogs/Incretin Mimetics	45
Amylin Mimetic	46
<i>TABLE 13 ORAL HYPOGYCEMICS</i>	46
MONITORING DEVICES FOR DIABETES	46
DIABETES THERAPY MARKET LEADERS	47
<i>FIGURE 2 DIABETES INSULIN THERAPY MARKET LEADERS, 2014 (% OF MARKET)</i>	47
<i>TABLE 14 TOP DIABETES DRUGS, BY DRUG AND MANUFACTURER</i>	48
DIABETES MARKET ANALYSIS	48

TOPIC	PAGE NO.
<i>TABLE 15 U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS, THROUGH 2020 (\$ MILLIONS)</i>	49
<i>TABLE 16 U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	49
SENSORY IMPAIRMENTS	49
<i>TABLE 17 U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS AND PRODUCTS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	50
SPEECH IMPAIRMENT	50
WRITING DIFFICULTY	50
VISION IMPAIRMENT	50
<i>TABLE 18 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS OVER 40, 2010*</i>	50
<i>TABLE 19 U.S. MARKET FOR PRESCRIPTION DRUGS AND SURGERY TO TREAT EYE DISEASES IN INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 (\$ MILLIONS)</i>	51
Macular Degeneration	51
<i>TABLE 20 U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	52
Cataracts	52
<i>TABLE 21 U.S. MARKET FOR CATARACT SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	53
Glaucoma	53
Ethnic Disparities	53
Glaucoma Prescription Market	54
<i>TABLE 22 U.S. MARKET FOR GLAUCOMA PRESCRIPTION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	54
Eyewear	54
Market for Eyewear Products for Individuals Over 65	54
<i>TABLE 23 U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	55
HEARING IMPAIRMENT	55
Causes of Hearing Loss	55
Market Analysis for Hearing Aid Products	56
<i>TABLE 24 U.S. MARKET FOR HEARING AID PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	56
NEUROLOGICAL DISEASES	56
<i>TABLE 25 U.S. MARKET FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65 BY DISEASE, THROUGH 2020 (\$ MILLIONS)</i>	57
ALZHEIMER'S DISEASE	57
<i>FIGURE 3 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%)</i>	58
Economic Burden	58
Current Treatments for Alzheimer's	59
<i>TABLE 26 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2015</i>	59
Market Analysis for Dementia Costs	60
<i>TABLE 27 U.S. MARKET FOR DEMENTIA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	60
DEPRESSION	61
Origins of the Disease	61
Genetic Factors	61
Biological Factors	61

TOPIC	PAGE NO.
Sociological Factors	61
Psychological Factors	62
Costs of Depression	62
Market Analysis for Depression in the Elderly	62
<i>TABLE 28 U.S. MARKET FOR DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	62
LIQUID NUTRITIONAL SUPPLEMENTS	63
<i>TABLE 29 U.S. MARKET FOR LIQUID NUTRITIONAL SUPPLEMENTS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	63
ORTHOPEDIC	63
<i>TABLE 30 U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND SURGERIES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 (\$ MILLIONS)</i>	64
OSTEOPOROSIS	64
<i>TABLE 31 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR OSTEOPOROSIS</i>	64
Osteoporosis Medications	65
<i>TABLE 32 OSTEOPOROSIS MEDICATIONS BY TYPE</i>	65
Market Analysis for Osteoporosis Medications	66
<i>TABLE 33 U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	66
FALLS AND THE ELDERLY	66
JOINT REPLACEMENT	66
Market Analysis	67
<i>TABLE 34 U.S. MARKET FOR SELECTED ORTHOPEDIC SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	67
RESPIRATORY	67
<i>TABLE 35 U.S. MARKET FOR RESPIRATORY MEDICATIONS AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	67
ALLERGIES	68
Current Treatments for Allergies	68
<i>TABLE 36 CURRENT ALLERGY TREATMENTS</i>	68
Allergy Market Analysis	70
<i>TABLE 37 U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	70
ASTHMA	71
Treatments	71
<i>TABLE 38 U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	72
COPD	72
<i>TABLE 39 U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	73
COPD Treatment Options	73
<i>TABLE 40 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S.</i>	73
Emphysema	74
Chronic Bronchitis	75
OXYGEN THERAPY	75
<i>TABLE 41 U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	75
LOSS OF PATENT PROTECTION	75

TOPIC	PAGE NO.
<i>TABLE 42 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN 2014-2021</i>	76
OTHER CHRONIC CONDITIONS	76
DENTAL HEALTH	76
OBESITY	77
PAIN MANAGEMENT	77
UROLOGICAL PROBLEMS	77
<i>TABLE 43 U.S. MARKET FOR UROLOGICAL PRODUCTS FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 (\$ MILLIONS)</i>	77
Incontinence Medications	78
<i>TABLE 44 U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	78
Benign Prostatic Hyperplasia (BPH)	78
<i>TABLE 45 SELECTED MEDICATIONS FOR BPH</i>	79
<i>TABLE 46 U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	79
ACQUISITIONS AND MERGERS IN THE ELDER CARE PHARMACEUTICAL INDUSTRY	80
<i>TABLE 47 SELECTED ACQUISITIONS AND MERGERS IN THE ELDER CARE PHARMACEUTICAL MARKET, 2013 TO 2015 (\$ MILLIONS)</i>	80
CHAPTER 5 INDUSTRY TRENDS BY SECTOR - HOUSING	82
UNPAID CAREGIVERS	82
TOLL ON CAREGIVERS	82
LONG-TERM CARE	83
<i>TABLE 48 LONG-TERM INSURANCE CARRIERS, 2015</i>	83
LONG-TERM CARE NEEDS	83
<i>FIGURE 4 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65 (%)</i>	83
U.S. HOUSING FOR INDIVIDUALS OVER 65	84
MARKET ANALYSIS	84
<i>TABLE 49 U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	85
AT-HOME REMODELING	85
<i>TABLE 50 U.S. MARKET FOR AT-HOME REMODELING FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	86
HOME HEALTHCARE SERVICES	86
<i>TABLE 51 U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	87
ADULT DAY CENTERS	87
<i>TABLE 52 U.S. MARKET FOR ADULT DAY CARE SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	88
COMPETITIVE LANDSCAPE FOR HOME HEALTHCARE SERVICES	88
<i>FIGURE 5 TOP HOME HEALTHCARE PROVIDERS, BY COMPANY AND PERCENT OF MARKET (%)</i>	88
HOUSING FOR LOWER INCOME INDIVIDUALS	89
INSTITUTIONAL CARE ALTERNATIVES FOR SENIORS	89
ASSISTED LIVING, SKILLED NURSING, MEMORY CARE PROVIDERS	90
<i>TABLE 53 U.S. MARKET FOR ASSISTED LIVING AND SKILLED NURSING FACILITIES FOR INDIVIDUALS OVER 65 BY SERVICE, THROUGH 2020 (\$ MILLIONS)</i>	90

TOPIC	PAGE NO.
TOP INDUSTRY PROVIDERS	90
<i>TABLE 54 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2014</i>	91
<i>TABLE 55 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2014</i>	91
<i>FIGURE 6 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN THE U.S., 2014 (%)</i>	91
<i>TABLE 56 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2015</i>	93
ASSISTED LIVING	93
OCCUPANCY RATES	93
SKILLED NURSING HOMES	93
MEMORY CARE	94
MARKET CONSTRAINTS	94
RESTRICTED SUPPLY OF NURSING BEDS	94
COST CONTAINMENT EFFORTS BY GOVERNMENT PAYERS	95
IMPLICATIONS OF THE AFFORDABLE CARE ACT (ACA)	95
Care Coordination	95
REIMBURSEMENT ISSUES	96
Medicaid Reimbursement	96
LACK OF FINANCIAL RESOURCES BY SENIORS	96
INDUSTRY COMPETITION	96
<i>TABLE 57 SELECTED ACQUISITIONS AND MERGERS IN THE SENIOR HOUSING MARKET, 2013-2015 (\$ MILLIONS)</i>	97
RETAINING COMPETENT STAFF	97
INDEPENDENT LIVING	97
INDEPENDENT LIVING/ACTIVE ADULT COMMUNITIES	98
RECREATIONALLY BASED RETIREMENT COMMUNITIES	98
<i>TABLE 58 U.S. MARKET FOR INDEPENDENT LIVING HOUSING FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	99
SENIOR HOUSING MARKET OPPORTUNITIES	99
MEMORY CARE FACILITIES	99
AGING IN PLACE	99
CHAPTER 6 INDUSTRY TRENDS, BY SECTOR - ASSISTIVE TECHNOLOGIES	101
PROJECTED ASSISTIVE TECHNOLOGIES MARKET	101
<i>TABLE 59 U.S. ASSISTIVE TECHNOLOGY MARKET BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	102
ASSISTIVE TECHNOLOGIES MARKET ANALYSIS FOR INDIVIDUALS OVER 65	102
<i>TABLE 60 U.S. MARKET FOR ASSISTIVE TECHNOLOGIES FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	102
<i>FIGURE 7 U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS OVER 65, 2015 AND 2020 (%)</i>	103
MEDICAL AND PERSONAL MONITORING AIDS	104
ACTIVITY LOCATION/PERSONAL MONITORING AIDS	104
Activity/Emergency Location Monitors	104
Remote Medical Monitors	104
Market Fragmentation	104
MEDICAL/PERSONAL MONITORING AIDS MARKET GROWTH	105
<i>TABLE 61 U.S. MARKET FOR MEDICAL/PERSONAL MONITORING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	105
MARKET DRIVERS FOR MEDICAL AND PERSONAL MONITORING AIDS	105

TOPIC	PAGE NO.
ACCESS AIDS	105
HOME ELEVATORS	105
WHEELCHAIR LIFTS	106
STAIR CLIMBERS	106
ACCESSIBLE BATHS AND SHOWERS	106
TRANSFER LIFTS	106
DOOR OPENERS	106
ACCESS AIDS MANUFACTURERS	106
<i>TABLE 62 ACCESS AIDS MANUFACTURERS</i>	106
<i>TABLE 63 U.S. MARKET FOR ACCESS AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	107
DAILY LIVING AIDS	108
<i>TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS</i>	108
PROJECTED MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65	108
<i>TABLE 65 U.S. MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	108
MOBILITY AIDS	109
<i>TABLE 66 U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65 BY PRODUCT, THROUGH 2020 (\$ MILLIONS)</i>	109
WHEELCHAIRS, SCOOTERS AND ACCESSORIES	109
Wheelchairs	109
<i>TABLE 67 WHEELCHAIR MANUFACTURERS</i>	110
Scooters	111
<i>TABLE 68 SCOOTER MANUFACTURERS</i>	111
AMBULATORY AIDS	111
<i>TABLE 69 U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	111
<i>TABLE 70 AMBULATORY AID MANUFACTURERS</i>	112
MOTOR VEHICLE MODIFICATIONS	112
<i>TABLE 71 U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	113
<i>TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS</i>	113
NAVIGATION AIDS	113
<i>TABLE 73 U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	113
OTHER AIDS	114
<i>TABLE 74 U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65 BY TYPE OF AID, THROUGH 2020 (\$ MILLIONS)</i>	114
BEDS	114
ERGONOMIC AIDS	114
COMMUNICATION AIDS	115
<i>TABLE 75 U.S. MARKET FOR COMMUNICATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)</i>	115
Speech Aids	115
Writing Aids/Computer Access	115
Input Devices	116
Output Devices	116
Software Products	116
Telephony Accessories	116

TOPIC	PAGE NO.
Text Telephones	116
Amplified Telephones	116
Vision/Reading Aids	116
CHAPTER 7 DEVELOPMENTAL PIPELINE FOR ELDER CARE PHARMACEUTICALS	119
<i>TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2014</i>	119
CANCER	120
BREAST	120
<i>TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER</i>	120
COLORECTAL CANCER	120
<i>TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER</i>	121
BLADDER	121
<i>TABLE 79 MAJOR PRODUCT PIPELINES FOR BLADDER CANCER</i>	121
PROSTATE	121
<i>TABLE 80 MAJOR PRODUCT PIPELINES FOR PROSTATE CANCER</i>	122
SKIN	122
<i>TABLE 81 MAJOR PRODUCT PIPELINES FOR SKIN CANCER</i>	122
DIABETES	123
<i>TABLE 82 MAJOR PRODUCT PIPELINES FOR DIABETES</i>	123
EYE DISEASES	124
<i>TABLE 83 MAJOR PRODUCT PIPELINE FOR EYE DISEASES</i>	124
HEART DISEASE/STROKE	124
<i>TABLE 84 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE</i>	125
KIDNEY DISEASE	126
<i>TABLE 85 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE</i>	126
MUSCULOSKELETAL	126
OSTEOPOROSIS	126
<i>TABLE 86 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS</i>	127
Rheumatoid Arthritis	127
<i>TABLE 87 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS</i>	127
NEUROLOGICAL	128
DEPRESSION PRODUCT PIPELINE	128
<i>TABLE 88 MAJOR PRODUCT PIPELINES FOR DEPRESSION</i>	128
DEMENCIA PRODUCT PIPELINE	128
<i>TABLE 89 MAJOR PRODUCT PIPELINE FOR DEMENCIA PHARMACEUTICALS</i>	129
RESPIRATORY	129
ASTHMA	129
<i>TABLE 90 MAJOR PRODUCT PIPELINES FOR ASTHMA</i>	129
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)	130
<i>TABLE 91 MAJOR PRODUCT PIPELINES FOR COPD</i>	130
CHAPTER 8 COMPANY DIRECTORY	133
HEALTHCARE	133
ABBOTT LABORATORIES	133
Business Overview	133
Products	133
ALLERGAN (FORMERLY ACTAVIS)	134

TOPIC	PAGE NO.
Business Overview	134
Products	134
ASTRAZENECA PLC	134
Business Overview	134
Products	134
BRISTOL-MYERS SQUIBB	135
Business Overview	135
Products	135
CENTOCOR (SEE JANSSEN PHARMACEUTICALS)	135
COVIDIEN (SEE MEDTRONIC)	135
ELI LILLY	135
Business Overview	135
Products	135
ENDO PHARMACEUTICALS INC.	136
Business Overview	136
Products	136
FOREST PHARMACEUTICALS (SEE ACTAVIS)	136
GLAXOSMITHKLINE PLC	136
Business Overview	136
Products	137
JANSSEN PHARMACEUTICALS INC.	137
Business Overview	137
Products	137
JOHNSON & JOHNSON	137
Business Overview	137
Products	138
MERCK	138
Business Overview	138
Products	138
NOVARTIS INTERNATIONAL AG/SANDOZ	138
Business Overview	138
Products	139
NOVO NORDISK	139
Business Overview	139
Products	139
PFIZER	139
Business Overview	139
Products	140
PURDUE PHARMACEUTICALS LP	140
Business Overview	140
Products	140
ROCHE PHARMACEUTICALS	140
Business Overview	140
Products	141
SANOFI-AVENTIS	141
Business Overview	141
Products	141

TOPIC	PAGE NO.
TAKEDA PHARMACEUTICALS	141
Business Overview	141
Products	142
MEDICAL DEVICES	142
BOSTON SCIENTIFIC	142
Business Overview	142
Products	142
DJO GLOBAL INC.	142
Business Overview	142
Products	143
MEDTRONIC INC.	143
Business Overview	143
Products	143
ST. JUDE MEDICAL INC.	143
Business Overview	143
Products	144
HOUSING OPTIONS	144
BROOKDALE SENIOR LIVING	144
Business Overview	144
Products	144
CAPITAL SENIOR LIVING CORP.	144
Business Overview	145
Products	145
ENLIVANT (FORMERLY ASSISTED LIVING CONCEPTS LLC)	145
Business Overview	145
Products	145
EMERITUS CORP. (SEE BROOKDALE)	145
FIVE STAR QUALITY CARE INC.	145
Business Overview	145
Products	146
HCR MANORCARE INC.	146
Business Overview	146
Products	146
LIFE CARE CENTERS OF AMERICA	146
Business Overview	146
Products	146
LIVHOME INC.	147
Business Overview	147
Products	147
SUNRISE SENIOR LIVING INC.	147
Business Overview	147
Products	147
ASSISTIVE DEVICES	148
A&D MEDICAL/LIFESOURCE	148
Business Overview	148
Products	148
ALIMED INC.	148

TOPIC	PAGE NO.
Business Overview	148
Products	148
ALLIED HEALTHCARE PRODUCTS INC.	149
Business Overview	149
Products	149
AMERICAN MEDICAL ALERT CORP. (SEE TUNSTALL HEALTHCARE)	149
BAXTER INTERNATIONAL INC.	149
Business Overview	149
Products	149
BAYER AG (MILES-BAYER)	150
Business Overview	150
Products	150
BLUE CHIP MEDICAL PRODUCTS	150
Business Overview	150
Products	150
BRUNO INDEPENDENT LIVING AIDS INC.	150
Business Overview	151
Products	151
CARD GUARD AG	151
Business Overview	151
Products	151
COBOLT SYSTEMS LTD.	151
Business Overview	152
Products	152
DOLPHIN COMPUTER ACCESS LTD.	152
Business Overview	152
Products	152
DUXBURY SYSTEMS INC.	152
Business Overview	152
Products	152
ECHO THERAPEUTICS	153
Business Overview	153
Products	153
EXACT DYNAMICS B.V.	153
Business Overview	153
Products	153
FREEDOM SCIENTIFIC INC.	154
Business Overview	154
Products	154
FRESENIUS MEDICAL CARE AG & CO. KGAA	154
Business Overview	154
Products	154
GRAHAM-FIELD HEALTH PRODUCTS	154
Business Overview	155
Products	155
GW MICRO INC.	155
Business Overview	155

TOPIC	PAGE NO.
Products	155
HONEYWELL HOMMED	155
Business Overview	155
Products	156
HUMANWARE	156
Business Overview	156
Products	156
INCLINATOR COMPANY OF AMERICA	156
Business Overview	156
Products	156
INVACARE CORP.	157
Business Overview	157
Products	157
JOHNSON & JOHNSON	157
Business Overview	157
Products	157
KIMBERLY CLARK	157
Business Overview	158
Products	158
KROWN MANUFACTURING	158
Business Overview	158
Products	158
LIFE ALERT EMERGENCY RESPONSE	158
Business Overview	158
Products	158
LIFE GUARDIAN LLC	159
Business Overview	159
Products	159
LIFESCAN INC.	159
Business Overview	159
Products	159
LIFTAVATOR INC.	159
Business Overview	160
Products	160
MEDLINE INDUSTRIES INC.	160
Business Overview	160
Products	160
MEDTRONIC MINIMED	160
Business Overview	160
Products	160
NIPRO DIAGNOSTICS INC.	161
Business Overview	161
Products	161
NXSTAGE MEDICAL INC.	161
Business Overview	161
Products	161
OBS MEDICAL	161

TOPIC	PAGE NO.
Business Overview	162
Products	162
OMRON HEALTHCARE INC.	162
Business Overview	162
Products	162
OPTELEC (SEE FREEDOM SCIENTIFIC INC.)	162
OTTO BOCK HEALTHCARE LP	162
Business Overview	163
Products	163
PHILIPS LIFELINE SYSTEMS INC.	163
Business Overview	163
Products	163
PRIDE MOBILITY PRODUCTS CORP.	163
Business Overview	163
Products	164
PULSE METRIC INC.	164
Business Overview	164
Products	164
RESMED INC.	164
Business Overview	164
Products	164
ROCHE DIAGNOSTICS	165
Business Overview	165
Products	165
SAVARIA CORP.	165
Business Overview	165
Products	165
SCOTTCARE CARDIOVASCULAR SOLUTIONS	165
Business Overview	165
Products	166
SIEMENS HEARING INSTRUMENTS INC.	166
Business Overview	166
Products	166
STARKEY HEARING TECHNOLOGIES	166
Business Overview	166
Products	166
SUNRISE MEDICAL INC.	167
Business Overview	167
Products	167
SVENSKA CELLULOSA AKTIEBOLAGET SCA	167
Business Overview	167
Products	167
THORNDIKE PRESS	167
Business Overview	168
Products	168
THYSSENKRUPP NORTH AMERICA	168
Business Overview	168

TOPIC	PAGE NO.
Products	168
TUNSTALL AMERICAS	168
Business Overview	168
Products	168
TYCO INTERNATIONAL	169
Business Overview	169
Products	169
WIDEX A/S	169
Business Overview	169
Products	169
CHAPTER 9 GLOSSARY	171
ACTIVITIES OF DAILY LIVING (ADLS)	171
ALZHEIMER'S DISEASE	171
ARTHRITIS	171
ASSISTED LIVING	171
ASSISTIVE TECHNOLOGY	171
BABY BOOMER	171
CARDIOVASCULAR DISEASE	172
CAREGIVERS	172
CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD)	172
DEMENTIA	172
DIABETES	172
DURABLE MEDICAL EQUIPMENT	172
ELDER/SENIOR	173
GERONTOLOGY	173
HOSPICE CARE	173
INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADLS)	173
LONG-TERM CARE	173
PROSTHETICS AND ORTHOTICS	173

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES, 2014 (MILLIONS/%)	16
TABLE 2 ESTIMATED ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS, WITH PERCENT OF POPULATION BY U.S. STATE, 2014 (POPULATION/%)	17
TABLE 3 U.S. MARKET FOR HEALTHCARE MEDICATIONS, PRODUCTS AND SURGICAL PROCEDURES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 (\$ MILLIONS/%)	27
TABLE 4 U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	31
TABLE 5 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND MANUFACTURER	33
TABLE 6 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS, THROUGH 2020 (\$ MILLIONS)	36
TABLE 7 U.S. MARKET FOR CARDIOVASCULAR MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	36
TABLE 8 LEADING CANCER DRUG PRODUCTS, BY MANUFACTURER AND INDICATION, 2015	38
TABLE 9 U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH 2020 (\$ MILLIONS)	40
TABLE 10 U.S. MARKET FOR CANCER DRUGS FOR INDIVIDUALS OVER AGE 65, THROUGH 2020 (\$ MILLIONS)	41
TABLE 11 SULFONYLUREAS	44
TABLE 12 BIGUANIDES	44
TABLE 13 ORAL HYPOGYCEMICS	46
TABLE 14 TOP DIABETES DRUGS, BY DRUG AND MANUFACTURER	48
TABLE 15 U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS, THROUGH 2020 (\$ MILLIONS)	49
TABLE 16 U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	49
TABLE 17 U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS AND PRODUCTS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 (\$ MILLIONS)	50
TABLE 18 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS OVER 40, 2010*	50
TABLE 19 U.S. MARKET FOR PRESCRIPTION DRUGS AND SURGERY TO TREAT EYE DISEASES IN INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 (\$ MILLIONS)	51
TABLE 20 U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	52
TABLE 21 U.S. MARKET FOR CATARACT SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	53
TABLE 22 U.S. MARKET FOR GLAUCOMA PRESCRIPTION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	54
TABLE 23 U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	55
TABLE 24 U.S. MARKET FOR HEARING AID PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	56
TABLE 25 U.S. MARKET FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65 BY DISEASE, THROUGH 2020 (\$ MILLIONS)	57
TABLE 26 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2015	59

TABLE HEADING	PAGE NO.
TABLE 27 U.S. MARKET FOR DEMENTIA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	60
TABLE 28 U.S. MARKET FOR DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	62
TABLE 29 U.S. MARKET FOR LIQUID NUTRITIONAL SUPPLEMENTS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	63
TABLE 30 U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND SURGERIES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 (\$ MILLIONS)	64
TABLE 31 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR OSTEOPOROSIS	64
TABLE 32 OSTEOPOROSIS MEDICATIONS BY TYPE	65
TABLE 33 U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	66
TABLE 34 U.S. MARKET FOR SELECTED ORTHOPEDIC SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	67
TABLE 35 U.S. MARKET FOR RESPIRATORY MEDICATIONS AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	67
TABLE 36 CURRENT ALLERGY TREATMENTS	68
TABLE 37 U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 (\$ MILLIONS)	70
TABLE 38 U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	72
TABLE 39 U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	73
TABLE 40 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S.	73
TABLE 41 U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	75
TABLE 42 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN 2014-2021	76
TABLE 43 U.S. MARKET FOR UROLOGICAL PRODUCTS FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 (\$ MILLIONS)	77
TABLE 44 U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	78
TABLE 45 SELECTED MEDICATIONS FOR BPH	79
TABLE 46 U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	79
TABLE 47 SELECTED ACQUISITIONS AND MERGERS IN THE ELDER CARE PHARMACEUTICAL MARKET, 2013 TO 2015 (\$ MILLIONS)	80
TABLE 48 LONG-TERM INSURANCE CARRIERS, 2015	83
TABLE 49 U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	85
TABLE 50 U.S. MARKET FOR AT-HOME REMODELING FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	86
TABLE 51 U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	87
TABLE 52 U.S. MARKET FOR ADULT DAY CARE SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	88
TABLE 53 U.S. MARKET FOR ASSISTED LIVING AND SKILLED NURSING FACILITIES FOR INDIVIDUALS OVER 65 BY SERVICE, THROUGH 2020 (\$ MILLIONS)	90
TABLE 54 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2014	91
TABLE 55 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2014	91
TABLE 56 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2015	93

TABLE HEADING	PAGE NO.
TABLE 57 SELECTED ACQUISITIONS AND MERGERS IN THE SENIOR HOUSING MARKET, 2013-2015 (\$ MILLIONS)	97
TABLE 58 U.S. MARKET FOR INDEPENDENT LIVING HOUSING FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	99
TABLE 59 U.S. ASSISTIVE TECHNOLOGY MARKET BY TYPE, THROUGH 2020 (\$ MILLIONS)	102
TABLE 60 U.S. MARKET FOR ASSISTIVE TECHNOLOGIES FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 (\$ MILLIONS)	102
TABLE 61 U.S. MARKET FOR MEDICAL/PERSONAL MONITORING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	105
TABLE 62 ACCESS AIDS MANUFACTURERS	106
TABLE 63 U.S. MARKET FOR ACCESS AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	107
TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS	108
TABLE 65 U.S. MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	108
TABLE 66 U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65 BY PRODUCT, THROUGH 2020 (\$ MILLIONS)	109
TABLE 67 WHEELCHAIR MANUFACTURERS	110
TABLE 68 SCOOTER MANUFACTURERS	111
TABLE 69 U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	111
TABLE 70 AMBULATORY AID MANUFACTURERS	112
TABLE 71 U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	113
TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS	113
TABLE 73 U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	113
TABLE 74 U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65 BY TYPE OF AID, THROUGH 2020 (\$ MILLIONS)	114
TABLE 75 U.S. MARKET FOR COMMUNICATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 (\$ MILLIONS)	115
TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2014	119
TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER	120
TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER	121
TABLE 79 MAJOR PRODUCT PIPELINES FOR BLADDER CANCER	121
TABLE 80 MAJOR PRODUCT PIPELINES FOR PROSTATE CANCER	122
TABLE 81 MAJOR PRODUCT PIPELINES FOR SKIN CANCER	122
TABLE 82 MAJOR PRODUCT PIPELINES FOR DIABETES	123
TABLE 83 MAJOR PRODUCT PIPELINE FOR EYE DISEASES	124
TABLE 84 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE	125
TABLE 85 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE	126
TABLE 86 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS	127
TABLE 87 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS	127
TABLE 88 MAJOR PRODUCT PIPELINES FOR DEPRESSION	128
TABLE 89 MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS	129
TABLE 90 MAJOR PRODUCT PIPELINES FOR ASTHMA	129
TABLE 91 MAJOR PRODUCT PIPELINES FOR COPD	130

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, 2015 AND 2020 (%)	9
FIGURE 1 FUTURE BURDEN OF ARTHRITIS FOR INDIVIDUALS OVER 65 IN THE U.S. BY GENDER, 2010-2030 (\$ MILLIONS)	30
FIGURE 2 DIABETES INSULIN THERAPY MARKET LEADERS, 2014 (% OF MARKET)	47
FIGURE 3 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%)	58
FIGURE 4 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65 (%)	83
FIGURE 5 TOP HOME HEALTHCARE PROVIDERS, BY COMPANY AND PERCENT OF MARKET (%)	88
FIGURE 6 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN THE U.S., 2014 (%)	91
FIGURE 7 U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS OVER 65, 2015 AND 2020 (%)	103